Freytes C O, Reid P, Smith K L
University of Tennessee Center for the Health Sciences, Memphis.
J Surg Oncol. 1990 Oct;45(2):99-102. doi: 10.1002/jso.2930450208.
Long-term experience with totally implanted catheter systems (TICS) is limited. We retrospectively evaluated the performance and long-term complications of TICS for intravenous infusion in cancer patients; 134 systems were implanted in 128 patients. The median duration of implantation was 144 weeks with 49 systems implanted for more than one year. Complications related to surgical factors included malposition of reservoir (2%), skin perforation or wound dehiscence (1.5%) and pneumothorax (less than 1%). Complications not related to surgical factors included: drug extravasation (1.5%), mechanical malfunction (1.5%), vein thrombosis (less than 1%), clotting of the reservoir or catheter (2%), skin infection (1.5%), and sepsis (less than 1%). The total complication rate was 13%. Most complications resolved spontaneously or with medical treatment and only 6 patients (4.6%) required re-implantation of a second system. We conclude that with long-term usage of TICS, the complication rate remains low, making it a safe and viable alternative for patients requiring long-term intravenous therapy.
全植入式导管系统（TICS）的长期应用经验有限。我们回顾性评估了TICS在癌症患者静脉输注中的性能及长期并发症；128例患者植入了134套系统。植入的中位持续时间为144周，49套系统植入时间超过一年。与手术因素相关的并发症包括储液器位置不当（2%）、皮肤穿孔或伤口裂开（1.5%）和气胸（不到1%）。与手术因素无关的并发症包括：药物外渗（1.5%）、机械故障（1.5%）、静脉血栓形成（不到1%）、储液器或导管凝血（2%）、皮肤感染（1.5%）和败血症（不到1%）。总并发症发生率为13%。大多数并发症可自行缓解或经药物治疗后缓解，仅6例患者（4.6%）需要再次植入第二个系统。我们得出结论，随着TICS的长期使用，并发症发生率仍然较低，这使其成为需要长期静脉治疗患者的一种安全可行的选择。
